1) ectylurea
依克替脲
2) etimicin
依替米星
1.
The study of the stability of etimicin in different menstruums;
依替米星在不同溶媒中的稳定性研究
2.
Comparison of Clinical Effect and Safety of Etimicin and Amikacin;
依替米星与阿米卡星临床疗效及安全性比较
3.
A Meta-Analysis on Treatment of Bacterial Infections with Randomized Control Study of Etimicin versus Import Netilmicin;
依替米星与进口奈替米星随机对照治疗细菌感染的Meta分析
3) eptifibatide
依替巴肽
1.
Platelet glycoproteinⅡb/Ⅲa receptor antagonist:eptifibatide;
血小板糖蛋白Ⅱb/Ⅲa受体拮抗药依替巴肽
2.
Eptifibatide or tirofiban was predominantly initiated in the catheter laboratory before the intervention.
目的探讨依替巴肽与替罗非班在急性冠状动脉综合征(ACS)介入治疗中的临床疗效和安全性。
4) acitretin
依曲替酸
1.
Synergistic effects of acitretin and narrow-band ultraviolet-B in inducing retinoic acid receptor gamma mRNA expression in normal human keratinocytes;
依曲替酸和窄谱中波紫外线对正常人角质形成细胞维甲酸受体γ mRNA表达的协同影响
2.
Inducement of acitretin to apoptosis of cutaneous squamous cell carcinoma cell line SCL-1 by upregulating Fas expression;
依曲替酸诱导皮肤鳞状细胞癌细胞系SCL-1凋亡及其机制的初步研究
3.
Objective To investigate effects of FY-10 and Acitretin on peripheral blood neutrophils(polymorphonuclear leukocytes;PMN) migration of patients with psoriasis vulgaris.
目的研究FY-10、依曲替酸对寻常型银屑病患者外周血中性粒细胞趋化功能的影响作用,探讨维A酸治疗银屑病的作用机制。
5) irinotecan
依立替康
1.
Combination chemotherapy with irinotecan and cisplatin as second-line treatment for small cell lung cancer;
依立替康联合顺铂二线治疗小细胞肺癌
2.
A randomized controlled clinical trial on irinotecan/cisplatin versus gemcitabine/cisplatin as the first-line treatment in advanced non-small cell lung cancer;
依立替康/顺铂与吉西他滨/顺铂方案一线治疗晚期非小细胞肺癌随机对照临床研究
3.
Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer:A Systematic Review
依立替康联合顺铂与足叶乙甙联合顺铂治疗广泛期小细胞肺癌的系统评价
6) ezetimibe
依替米贝
1.
Study on the Synthesis of Intermediate of Ezetimibe;
依替米贝中间体合成研究
补充资料：西索米星
分子式：C19H37N5O7
分子量：447.53
CAS号：32385-11-8
性质：暂无
制备方法：暂无
用途：用于绿脓杆菌、肠杆菌等革兰氏阴性菌感染。
分子量：447.53
CAS号：32385-11-8
性质：暂无
制备方法：暂无
用途：用于绿脓杆菌、肠杆菌等革兰氏阴性菌感染。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条